Unbound free fatty acids and heart-type fatty acid-binding protein: diagnostic assays and clinical applications.
The release of cardiac biomarkers is influenced by a variety of factors:
* Cytosolic enzymes: An increase in intracellular calcium activates a variety of enzymes, including phospholipases and the protease calpase. Calpase contributes to the early degradation, dissociation, and release of myo-fibrillar proteins (such as cTnI and cTnT) after myocardial damage. pH-dependent dissociation of structural proteins could also affect release of such markers. On the other hand, lysosomes are stable within the first 3-4 h after onset of ischemia and do not affect the breakdown of subcellular structures.
* Subcellular location: Soluble cytosolic molecules, such as fatty acid-binding proteins (FABPs), are released more rapidly than structurally bound molecules.
* Molecular mass: Within a particular intracellular localization, smaller molecules such as myoglobin and FABPs may enter the vascular system to a large extent directly via the microvascular endothelium.
* Plasma clearance: Smaller molecules such as FABPs (also myoglobin) pass through the glomerular membranes and are reabsorbed and metabolized in tubular epithelial cells (2). Falsely increased plasma concentrations (caused by impaired clearance attributable to renal failure) or falsely decreased concentrations (in patients with hypermetabolic states) for both markers may therefore be observed.
* Concentration gradients: Concentration gradients between cardiomyocytes and interstitial spaces as well as local blood and lymphatic flow may also affect the appearance of markers in the general circulation.
Whether the release of biomarkers from the injured myocardium indicates irreversible damage and cardiac necrosis remains an issue of debate. The classic hypothesis suggests that release of biomarkers from the cardiomyocyte is possible only from irreversibly injured myocytes and is based on the hypothesis that plasma membranes are physiologically impermeable to macromolecules (3). An alternative hypothesis proposes that release is a metabolically controlled property of cell membranes and that small extracellular increases in cardiac biomarkers may be caused by reversible disturbance of cell metabolism (4). Recent evidence suggests that under moderate ischemic stress, myocardial tissue can release small amounts of macromolecules from the cytosol by mechanical mechanisms other than persistent membrane perforation (4). The prevention of membrane leaks is an energy-dependent process in which myocardial plasma membranes become permeable to intracellular macromolecules under conditions of energy shortage. However, the appearance of mitochondrial enzymes and prolonged increases in cardiac proteins in serum are generally accepted as indicators of myocardial necrosis.
Testing the specificity of novel biomarkers of ischemia is challenged by the absence of a "gold standard" for myocardial ischemia. Comparison with troponin concentrations will not be valid because the ischemia marker would be expected to increase in unstable angina patients, who should not have any detectable increases in cardiac troponins. Achieving clinical acceptance of the proposed biomarker as the new gold standard will require extensive laboratory and translational research.
In this review, we discuss the physiology and pathophysiology of unbound free fatty acids (FFAu) and heart-type FABP (H-FABP) and their proposed clinical applications as new biomarkers of cardiac ischemia and necrosis, respectively.
PHYSIOLOGY AND PATHOPHYSIOLOGY
FFAs play several essential roles in physiologic homeostasis. Under aerobic conditions, nonesterified long-chain FFAs represent the primary metabolic sources for the myocardium, accounting for almost two-thirds of the ATP generated, with glucose metabolism generating the remaining one-third of myocardial oxygen demand (5). Plasma long-chain fatty acids are either esterified to glycerol or nonesterified (or FFAs), most of which are bound to albumin. The mechanism for uptake of FFAs into myocytes remains unclear but involves passive diffusion and/or active carrier-mediated transport (6). In the cytoplasm, long-chain FFAs are bound to FABP, which presumably facilitates their transport to the outer mitochondrial membrane where they become esterified/activated by long-chain acyl-CoA synthetase (Fig. 1). Once activated, acyl-CoA esters are directed mainly to (3-oxidation, but some may be stored as triglycerides or converted into membrane phospholipids.
During hypoxia and ischemia, nonesterified fatty acids/FFAs have damaging effects on heart tissue and have been associated with an increased incidence of ventricular dysrhythmias and death in patients with acute myocardial infarction (AMI) (7, 8). Proposed mechanisms for the damaging effects of FFAs during ischemia include accumulation of toxic intermediates of fatty acid metabolism, suppression of glucose utilization, and uncoupling of oxidative metabolism from electron transfer (5). Inhibitors of FFA metabolism have been shown experimentally to reduce the infarct size and decrease the postischemic cardiac dysfunction in animal models (9). Shown in Table 1 is a comparison of [FFA.sub.u] and H-FABP concentrations in circulation and in myocytes under physiologic and ischemic conditions.
Although most of the FFAs in serum are bound to albumin, a small amount is unbound; this is frequently referred to as the "free" fraction. Serum [FFA.sub.u] concentrations are determined from the ratio of total serum FFAs to total serum albumin (10). A method for estimating serum FFA concentrations is based on the breakdown of pyrophosphate, which is formed by thioesterification of FFAs with ATP and CoA in the presence of acyl-CoA synthetase, to inorganic phosphate, which is measured by reaction with molybdate (11).
[FIGURE 1 OMITTED]
A recently developed method for measurement of serum [FFA.sub.u] uses a fluorescent probe of [FFA.sub.u], termed acrylodated intestinal fatty acid-binding protein (ADIFAB), which is prepared by derivatizing a recombinant intestinal FABP with the fluorescent molecule acrylodan (12). Binding of a single [FFA.sub.u] molecule to ADIFAB, which does not interact with other serum molecules, displaces the fluorescent tag, producing a spectral shift from 432 nm to 505 nm that can be measured with a fluorometer. Human serum contains a mixture of 6 FFAs: palmitate (25%), stearate (10%), oleate (38%), linoleate (22%), arachidonate (3%), and linolenate (2%) (13). Richieri and Kleinfeld (13) reported ADIFAB dissociation constants, determined at 37 [degrees]C and at concentrations below the critical micelle concentrations, of 0.31, 0.08, 0.28, 0.97,1.63, and 2.50 [mu]mol/L for palmitate, stearate, oleate, linoleate, arachidonate, and linolenate, respectively. Variations in dissociation constants are highly correlated with the solubility of the specific fatty acid in water, suggesting that all of these fatty acids bind to intestine FABP with a similar conformation.
A second-generation version of the assay uses a handheld reader and 15 [micro]L of plasma and provides turn-around times <1 min (14). The assay shows improved low-end sensitivity and is not affected by hemoglobin. The CV for duplicate measurements is 7%. The [FFA.sub.u] upper reference limit (URL), determined at the 97.5th percentile of value distribution, is 2.7 nmol/L [mean (SD), 1.5 (0.6) nmol/L; range, 0.6-4.5 nmol/L] (14).
Reports have suggested that heparin may cause FFA increases in vivo and perhaps in vitro as well. This is because heparin is known to stimulate the activity of lipoprotein lipase, which releases FFAs from triglycerides associated with blood lipoproteins. Blood collected into heparin-containing flasks or tubes or from patients receiving therapeutic heparin may therefore not be suitable for the [FFA.sub.u] test. There has been controversy regarding this issue, however. Thus, assays considered for clinical use must be evaluated in appropriate studies addressing the potential of heparin interference.
The mean (SD) serum [FFA.sub.u] concentration, measured with the ADIFAB assay, in 283 samples from healthy donors was 7.5 (2.5) nmol/L (13), and the distribution of [FFA.sub.u] values was independent of donor age and sex. Mean [FFA.sub.u] values increased significantly (by 1.5 nmol/L; P <0.001) after overnight fasting. The clinical uses of [FFA.sub.u] concentrations are summarized in Table 2.
Using the fluorescent probe ADIFAB, Kleinfeld et al. (15) measured serum [FFA.sub.u] concentrations in 22 patients 5 min before and 30 min after percutaneous transluminal coronary angioplasty (PCTA). Post-PCTA concentrations were higher than baseline values in all patients, with the mean [FFA.sub.u] concentration increasing 5-fold compared with the mean value [7.5 (2.5) nmol/L] observed in healthy patients. Ischemic ST changes monitored by electrocardiography (ECG) were observed in only 50% of patients. In addition, [FFA.sub.u] concentrations were significantly higher in the ECG-positive group than the ECG-negative group. An increase in [FFA.sub.u] concentrations was suggested as an early marker of ischemia caused by PCTA (15).
In a different study, 9 MI patients had increased [FFA.sub.u] concentrations, whereas only 2 of the 9 had increased cTnI (14). In addition, 93% and 30% of other chest pain patients had increased [FFA.sub.u] and cTnI concentrations, respectively. [FFA.sub.u] concentrations were increased in every instance that cTnI was increased. In addition, there was a positive correlation between peak [FFA.sub.u] and cTnI concentration. At presentation, all of the MI patients had increased [FFA.sub.u], whereas only 22% had increased cTnI. Some of these patients had additional diagnoses (such as cocaine abuse, sepsis, and cardiac contusion) that can cause myocardial ischemia and injury. The authors therefore proposed that [FFA.sub.u] concentrations may increase in the presence of acute myocardial injury independent of plaque rupture (14).
Circulating FFA concentrations have also been suggested as putative for ventricular arrhythmias and sudden death after MI (16). In the Paris Prospective Study I, plasma FFA concentrations were measured in a cohort of 5250 middle-aged men free of known ischemic cardiac disease (17). After 22 years of follow-up, increased FFA concentrations were found to be an independent risk factor for sudden death (relative risk, 1.70; 95% confidence interval, 1.21-2.13) but not for fatal MI.
Pirro et al. (18) examined the relationship between circulating FFA concentrations and risk of ischemic heart disease (IHD) in 2130 men with insulin resistance syndrome who were without IHD at enrollment. During a 5-year follow-up,114 of these individuals developed IHD. After adjustment for nonlipid risk factors, increased circulating FFA concentrations conferred a 2-fold increase in the risk of IHD (odds ratio, 2.1; P = 0.05) compared with lower plasma FFA concentrations. However, after adjustment for triglyceride concentrations, HDL-cholesterol, small, dense LDL, apolipoprotein B, and fasting plasma insulin, the relationship between plasma FFA concentrations and IHD did not achieve statistical significance.
In another study, [FFA.sub.u] concentrations were measured in serum samples from 458 AMI patients (75 females and 383 males), enrolled
in the TINA II trial (19), who were treated with tissue plasminogen activator (tPA) (20). [FFA.sub.u] concentrations were measured with the ADIFAB2 assay in blood samples drawn on admission and 50 min, 5 h, and 8 h after initiation of tPA treatment. Relative to the control population, results of this study indicated an ~4-fold increase in serum [FFA.sub.u] concentrations at enrollment, a further 2-fold increase after tPA administration, and then a gradual decrease within 5 h of tPA administration. At cutoff a 5 nmol/L, the predicted sensitivity was 98% based on the results for admission and 50-min samples. The specificity, based on comparison with healthy individuals and patients with noncardiovascular disease, was 93%. Although interesting, these data must be considered exploratory for indicating the potential clinical performance of [FFA.sub.u]. This is because the TIMI II trial included only well-characterized AMI patients, who were compared with patients with known noncardiovascular disease and with healthy individuals, which will not be the way the test will be used in practice. FFAs also correlated well with mortality at 30 days in the TIMI II cohort (20).
Current data, although limited, suggest that monitoring of [FFA.sub.u] concentrations in patients presenting with ischemic symptoms may provide an early indication of cardiac ischemia. Cohort trials that enroll a broad spectrum of suspected myocardial ischemia patients need to be performed to fully evaluate the true potential of this biomarker. ROC curves need to be plotted for relevant populations.
FABPs bind long-chain fatty acids reversibly and noncovalently. FABPs are relatively small (15 kDa) intracellular proteins that are abundantly produced in tissues having active fatty acid metabolism, including the heart, liver, and intestine (21). FABPs each contain 126-137 amino acids, and their tertiary structure resembles a clam shell in which the ligand is bound between the 2 halves of the clam by interaction with specific amino acid residues within the binding pocket, the so-called [beta]-barrel (22). Currently, 9 distinct FABP types have been identified, with each type showing a characteristic pattern of tissue distribution and a stable intracellular half-life of 2-3 days (21). H-FABP was first shown to be released from injured myocardium in 1988, after which several studies investigated its application as a biochemical marker of myocardial injury. The H-FABP isoform is produced not only in cardiomyocytes but also, to a lesser extent, in skeletal muscle (23), distal tubular cells of the kidney (24), specific parts of the brain (25), lactating mammary glands, and placenta (23). Human H-FABP contains 132 amino acid residues and is an acidic protein (pI 5) (26).
The primary biological function of FABPs is to facilitate intracellular translocation of long-chain fatty acids (see Fig. 1), which is usually hampered by the very low solubility of these compounds in aqueous solutions (21). H-FABP can therefore be regarded as the cytoplasmic counterpart of plasma albumin. H-FABP knock-out mice have a markedly lower (~50%)fatty acid uptake rate and oxidation (24). Other functions of H-FABP include participation in signal transduction pathways, such as regulation of gene expression by mediating fatty acid signal translocation to peroxisome proliferator-activated receptors (27), and putative protection of cardiac myocytes against the detergent-like effects of locally high concentrations of long-chain fatty acids, particularly during ischemia (21, 28).
The cellular production of FABPs is regulated primarily at the transcriptional level. In experimental animals, FABP was increased by endurance training (29) and diabetes (30).
IMMUNOLOGIC ASSAYS FOR H-FABP
The characteristics of several assays for human H-FABP are shown in Table 3. H-FABP is a stable protein; both plasma samples and recombinant protein solutions can be subjected to at least 8 freeze-thaw cycles without loss of immunoreactivity (31). Samples can be stored for at least 2 years at -80 [degrees]C (32). Recombinant H-FABP is immuno-chemically equivalent to the tissue-derived protein and generally serves as a calibration material in immunoassays (26, 31).
Tanaka et al. (2) developed a competitive enzyme immunoassay for H-FABP in plasma and urine samples. However, the assay required a long assay time and was not suitable for clinical application. Wodzig et al. (31) developed a one-step ELISA with a total performance time of 45 min; this assay has sensitivity and specificity comparable to the two-step ELISA developed by Okhura et al. (33). Both assays are commercially available and are used in clinical research.
Automated immunoassays. Several automated assays have been developed, including an enzyme immunoassay, an automated sandwich immunoassay (34), and a fully automated microparticle-enhanced immunoassay (COBAS[R] MIRA Plus analyzer; Hoffmann-La Roche). These assays use carboxylated latex particles coated with 3 monoclonal anti-human H-FABP antibodies (35) and are not commercially available at present. Very recently, a new concept of precipitation ellipsometry has been reported (36), with a rapid assay time of 10 min, but this assay is still in prototype form.
Lateral flow assays. Qualitative H-FABP lateral-flow assays have also been developed, and 2 whole-blood tests are commercially available (37-39). These qualitative tests have a 15-min analysis time, and the cutoff for normal vs high H-FABP concentrations is 6 [micro]g/L. Drawbacks of these lateral-flow assays include substantial interobserver differences in interpretation of color development and the inability to differentiate between moderate and high HFABP concentrations.
Immunosensors. Siegmann-Thos et al. (40) developed a sandwich immunoassay that uses glucose oxidase-labeled detection antibodies. In the current format, this system requires sample predilution and is susceptible to plasma matrix effects. Real-time optical immunosensors have been developed (41), but these require large sample volumes, have high detection limits, and are susceptible to interference from plasma lipids. As part of the EURO-CARDI project, Schreiber et al. (42) and Key et al. (43) developed the first amperometric immunosensor for plasma H-FABP measurement. This rapid 20-min semiautomated analyzer gave results comparable to those obtained with the ELISA developed by Wodzig et al. (31), but did not exhibit sufficient sensitivity in the low-normal concentration range of 5-15 [micro]g/L. In 2002, O'Reagan et al. (44) described an H-FABP immunosensor that used whole blood and had an assay time of 50 min.
Recently, a prototype of an online immunodisplacement sensor has been developed for continuous monitoring of H-FABP (45). In this immunosensor, blood samples are obtained via a microdialysis probe or via continuous ultrafiltration of venous blood.
CLINICAL INTERPRETATION OF PLASMA H-FABP CONCENTRATIONS
Under nonpathologic conditions, H-FABP is not present in plasma or interstitial fluid, and cytoplasmic concentrations of this protein are 2 x [10.sup.5]-fold higher than its vascular concentrations (46). The plasma H-FABP concentration measured in apparently healthy individuals (<5 [micro]g/L) is suggested to result from continuous release from damaged skeletal muscle cells.
The biological variation attributable to age, sex, and circadian rhythm significantly influences H-FABP reference values (47). Probably because of their larger muscle mass, men have higher plasma H-FABP concentrations than women. Because H-FABP is eliminated from the circulation predominantly by renal clearance (2) and renal function decreases with age, plasma H-FABP concentrations increase during aging. In addition, H-FABP release from skeletal muscle may increase with age or exercise, as has been described for myoglobin (48). A URL of 6 [micro]g/L has been proposed independently by several groups (47, 49). Selected studies indicating key clinical uses of H-FABP are summarized in Table 4.
CLINICAL APPLICATIONS OF H-FABP
Early marker of AMI. H-FABP was initially reported to be rapidly released from injured myocardium (50). Because of the recent redefinition of MI (51), biochemical markers have become even more important for assessment of suspected cardiac ischemia patients with non-ST-segment elevation. Because the plasma release characteristics of H-FABP after myocardial injury closely resemble those of myoglobin (52), the application of H-FABP as a sensitive early marker for myocardial injury has been investigated by several groups (53). In general, H-FABP was found to perform better than or similar to myoglobin (53). The areas under the ROC curves for these comparisons, which used the admission blood samples from all patients, were significantly larger for H-FABP than for myoglobin, indicating better performance of H-FABP within 6 h after onset of symptoms. Furthermore, subgroup analysis of patients presenting <6 h after onset of symptoms showed better performance for H-FABP compared with myoglobin (54). The observed higher sensitivity of H-FABP may be related to the higher cardiac tissue content of H-FABP compared with myoglobin. In addition, the reference values for H-FABP in plasma are far lower than those for myoglobin. Therefore, after myocardial injury, H-FABP increases to above the URL more rapidly than does myoglobin or troponin (54-56). This rapid increase to above the URL can also be used to further improve the diagnostic value of the marker (i.e., rule-out power) by use of sequential plasma H-FABP measurements. When they evaluated plasma H-FABP values at admission and 1-2 h after admission, Haastrup et al. (57) reported an increased probability of detecting an AMI.
Okamoto et al. (54) measured concentrations of HFABP, myoglobin, and CK-MB in 140 AMI patients, 49 non-AMI chest pain patients, and 75 healthy volunteers. The area under the ROC curve for H-FABP was significantly higher (0.921) than those of myoglobin (0.843) and CK-MB (0.654). In another study, H-FABP, cTnI, and creatine phosphokinase concentrations were measured in 218 patients with chest pain and suspected MI; 94 of these patients were eventually diagnosed with MI (55). HFABP showed 100% sensitivity and negative predictive value at 1 h after admission (55). The areas under the ROC curves for H-FABP, creatine phosphokinase, and cTnI calculated at admission and 1 h after admission were 0.871 and 0.995, 0.711 and 0.856, and 0.677 and 0.845, respectively (55). Measurement of H-FABP in serum or plasma was suggested to allow the earliest exclusion of non-AMI patients.
Seino et al. (56) compared the diagnostic efficacy of a newly developed whole blood rapid test for H-FABP with that of a rapid cTnT test in 129 consecutive patients with suspected cardiac ischemia, 31 of whom had a diagnosis of AMI. The respective temporal sensitivities of H-FABP and cTnT tests were 100% vs 50% at 3 h and 100% vs 100% at >12 h after onset of symptoms. The respective specificities were 63% vs 96.3% at 3 h and 75% vs 87.5% at >12 h. The negative predictive values were 100% vs 86.7% at 3 h and 100% vs 100% at >12 h. The rapid H-FABP assay was suggested to effectively exclude non-AMI patients within 3 h of onset (56).
Differentiation of cardiac and skeletal muscle injury. H-FABP is produced mainly in the heart, but to a lesser extent, it is also produced in skeletal muscle (58). When patients suffered skeletal muscle injury as a result of cardioversion, multiorgan failure, postoperative states, or vigorous exercise such as running (59) or rowing (60), H-FABP was released into the blood. The myoglobin/H-FABP ratio has been used to differentiate between heart muscle (ratio = 2-10) and skeletal muscles (ratio = 20-70), depending on the type of muscle (58). In patients with AMI, the plasma myoglobin/H-FABP ratio was ~5 during the entire period of increased plasma concentrations, whereas for patients with aortic surgery (causing no-flow ischemia of the lower extremities), the plasma myoglobin/H-FABP ratio was 45 (58). During defibrillation after AMI, the plasma myoglobin/H-FABP ratio increased from 8 to 60 in the 24 h after AMI as a result of injury of the intercostal pectoralis muscles (58). In cases in which a second increase in plasma concentrations of marker proteins occurs, this ratio can be used to differentiate a recurrent infarction (ratio remains at 2-10) from additional skeletal muscle injury (ratio increases to 20-70).
Infarct size, reperfusion, and coronary bypass grafting. To evaluate the effect of thrombolytic therapy, the size of a myocardial infarct can be estimated by measuring the cumulative release of H-FABP. In patients treated with standard thrombolytic therapy after AMI, plasma concentrations of H-FABP and myoglobin peaked at ~4 h after first symptoms, whereas creatine kinase (creatine phosphokinase or CK-MB) and lactate dehydrogenase peaked at ~12 and 20 h, respectively (52). Because H-FABP and myoglobin rapidly return to their respective URLs (within 24 h after AMI) as a result of renal clearance (23, 52), both proteins can be used to assess a recurrent infarction within 10 h after first AMI (58), which might be missed by CK-MB, cTnT, and cTnI because plasma concentrations of these markers return much more slowly to reference values (61, 62). If no thrombolytic therapy is administered, the H-FABP concentration in plasma peaks at 8 h and returns to within reference values after only 36 h, comparable to myoglobin (62). These differences in release kinetics do not impact the measurement of cardiac proteins in plasma, however (32, 58, 62). Because H-FABP is cleared by the kidneys, renal insufficiency could potentially impact its clinical utility; however, data from de Groot et al. (32) indicate that individually estimated clearance rates can be applied successfully for infarct size estimation.
The rapid release of H-FABP can also be used for the detection of successful coronary reperfusion in patients with AMI (63-65). Both plasma H-FABP and myoglobin were found to increase sharply after successful reperfusion, but in patients with failed reperfusion, both proteins increased more slowly. The relatively low sensitivity and specificity of ~70% could be improved to 80% by normalization to infarct size.
The characteristics of rapid release and ability to differentiate between skeletal or cardiac muscle injury can be useful for early detection of postoperative myocardial tissue loss in patients undergoing coronary bypass surgery (66).
Clinical assessment of congestive heart failure (CHF). Preliminary studies in patients with CHF indicate that increased plasma concentrations of H-FABP and cTnT are associated with progressive deterioration of ventricular function and a worse prognosis (67). H-FABP concentrations were related not only to CHF severity (New York Heart Association classes 3 and 4) and serum cTnT concentrations (67), but also to the occurrence of recurrent cardiac events (68, 69). Knowledge regarding the significance of H-FABP as a marker of myocardial injury in CHF is continuing to evolve and needs further study.
Prognostic value. In the early hours of acute coronary syndrome (ACS), selection of patients who are at high risk for cardiac events is an important factor for determining the appropriate treatment strategy. The use of plasma H-FABP concentrations for early prediction of adverse clinical outcomes in patients with suspected ACS has only recently been the subject of investigation but shows promising results; increased plasma H-FABP concentrations significantly correlated with increased cardiac event rates and cardiac mortality (70,71). Pelsers et al. (68) showed that when plasma H-FABP was <6 [micro]g/L, the negative predictive value for a recurrent event in CHF patients within 90 days was 81%, whereas cTnT <0.02 [micro]g/L had a negative predictive value of 57%. This difference is most likely explained by insufficient sensitivity of the cTnT assay. Although for cTnT a cutoff value of 0.1 [micro]g/L for indication of myocardial injury is commonly used, cutoff values of 0.05 and 0.02 [micro]g/L are now being evaluated for more sensitive immunoassays.
H-FABP AS A POTENTIAL MARKER OF CARDIAC ISCHEMIA
Although H-FABP is generally regarded as a marker of necrosis, one recent study has indicated its additional potential utility as a marker of ischemia (72). H-FABP concentrations measured in pericardial fluid samples collected immediately after median sternotomy were significantly increased in 17 patients with unstable angina who had anggnnl symptoms and/or ST changes compared with 17 other patients who did not have these symptoms [mean (SD) values were 16.3 (2.0) vs 9.6 (1.0) [micro]g/L; P = 0.0046]. H-FABP secretion into the interstitial space may be mediated by increased permeability of the myocardial cell membrane associated with severe ischemia.
The main advantage of H-FABP is its ability to exclude non-AMI patients very early after onset of symptoms. The fact that H-FABP may be present in the circulation in the absence of AMI makes it difficult to distinguish between patients with an AMI or unstable angina and warrants more investigation to definitively establish the diagnostic cutoff for H-FABP. In addition, only a few reports (68, 70, 71) have shown the prognostic value of H-FABP measurements in ACS patients. Further investigation of the prognostic value of H-FABP measurements is needed.
In combination with cardiac troponins, H-FABP may be useful to cover the complete diagnostic window of patients presenting with ACS in the emergency department, along with the electrocardiographic and clinical symptoms. Widespread availability on automated analyzers is necessary for routine applicability of H-FABP.
Preliminary data suggest that [FFA.sub.u] concentrations have potential in identifying patients with cardiac ischemia. More work is needed, however, to clinically validate this marker and to meet quality specifications.
H-FABP is a useful biomarker for detection of cardiac injury in ACS within 6 h of symptoms onset. Limitations include a lack of complete cardiac specificity, a relatively small diagnostic window of 24-30 h after the acute event, and the probability of falsely increased values in patients with renal insufficiency. Although a relatively small number of clinical studies have been performed (12 studies involving a total of 2130 patients), all of these studies showed better or similar performance of H-FABP compared with myoglobin for the early diagnosis of AMI. H-FABP also has prognostic value to predict recurrent cardiac events in patients with ACS or CHF. The use of H-FABP in ruling out MI in patients with ACS is promising but needs further study.
Portions of the FABP diagnostic studies performed in the laboratory of Jan F.C. Glatz (Netherlands Heart Foundation Professor of Cardiac Metabolism) were supported by the Ministry of Economic Affairs (BTS Grant 97.188) and the Dutch Technology Foundation (Grant GGN4860).
Received June 15, 2005; accepted October 21, 2005.
Previously published online at DOI: 10.1373/clinchem.2005.056143
(1.) Wu AHB, ed. Cardiac markers, 2nd ed. Totowa, NJ: Humana Press, 2003:467pp.
(2.) Tanaka T, Hirota Y, Sohmiya K, Nishimura S, Kawamura K. Serum and urinary human heart fatty acid-binding protein in acute myocardial infarction. Clin Biochem 1991;24:195-201.
(3.) Mair J. Tissue release of cardiac markers: from physiology to clinical applications. Clin Chem Lab Med 1999;37:1077-84.
(4.) Piper HM, Schwartz P, Spahr R, Hutter JF, Spieckermann PG. Early enzyme release from myocardial cells is not due to irreversible cell damage. J Mol Cell Cardiol 1984;16:385-8.
(5.) Liedtke AJ. Alterations of carbohydrate and lipid metabolism in the acutely ischemic heart. Prog Cardiovasc Dis 1981;23:321-36.
(6.) van der Vusse GJ, van Bilsen M, Glatz JF, Hasselbaink DM, Luiken JJ. Critical steps in cellular fatty acid uptake and utilization. Mol Cell Biochem 2002;239:9-15.
(7.) Oliver MF, Kurien VA, Greenwood TW. Relation between serum-free-fatty acids and arrhythmias and death after acute myocardial infarction. Lancet 1968;1:710-4.
(8.) Gupta DK, Jewitt DE, Young R, Hartog M, Opie LH. Increased plasma-free-fatty-acid concentrations and their significance in patients with acute myocardial infarction. Lancet 1969;2:1209-13.
(9.) Hendrickson SC, St Louis JD, Lowe JE, Abdel-aleem S. Free fatty acid metabolism during myocardial ischemia and repertusion [Review]. Mol Cell Biochem 1997;166:85-94.
(10.) Spector AA. Fatty acid binding to plasma albumin. J Lipid Res 1975;16:165-79.
(11.) Kiziltunc A, Akcay F. An enzymatic method for the determination of free fatty acids in serum/plasma. Clin Chem Lab Med 1998;36: 83-6.
(12.) Richieri GV, Ogata RT, Kleinfeld AM. A fluorescently labeled intestinal fatty acid binding protein. Interactions with fatty acids and its use in monitoring free fatty acids. J Biol Chem 1992;267: 23495-501.
(13.) Richieri GV, Kleinfeld AM. Unbound free fatty acid levels in human serum. J Lipid Res 1995;36:229-40.
(14.) Apple FS, Wu AH, Mair J, Ravkilde J, Panteghini M, Tate J, et al. Future biomarkers for detection of ischemia and risk stratification in acute coronary syndrome. Clin Chem 2005;51:810-24.
(15.) Kleinfeld AM, Prothro D, Brown DL, Davis RC, Richieri GV, DeMaria A. Increases in serum unbound free fatty acid levels following coronary angioplasty. Am J Cardiol 1996;78:1350-4.
(16.) Tansey MJ, Opie LH. Relation between plasma free fatty acids and arrhythmias within the first twelve hours of acute myocardial infarction. Lancet 1983;2:419-22.
(17.) Jouven X, Charles MA, Desnos M, Ducimetiere P. Circulating nonesterified fatty acid level as a predictive risk factor for sudden death in the population. Circulation 2001;104:756-61.
(18.) Pirro M, Mauriege P, Tchernof A, Cantin B, Dagenais GR, Despres JP, et al. Plasma free fatty acid levels and the risk of ischemic heart disease in men: prospective results from the Quebec Cardiovascular Study. Atherosclerosis 2002;160:377-84.
(19.) Comparison of invasive and conservative strategies after treatment with intravenous tissue plasminogen activator in acute myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) phase II trial. The TIMI Study Group. N Engl J Med 1989;320:618-27.
(20.) Kleinfeld AM, Kleinfeld KJ, Adams JE. Serum levels of unbound free fatty acids reveal high sensitivity for early detection of acute myocardial infarction in patients samples from the TIMI II trial. J Am Coll Cardiol 2002;39:312A.
(21.) Glatz JF, van der Vusse GJ. Cellular fatty acid-binding proteins: their function and physiological significance. Prog Lipid Res 1996;35:243-82.
(22.) Young AC, Scapin G, Kromminga A, Patel SB, Veerkamp JH, Sacchettini JC. Structural studies on human muscle fatty acid-binding protein at 1.4 P, resolution: binding interaction with three C18 fatty acids. Structure 1994;2:523-34.
(23.) Zschiesche W, Kleine AH, Spitzer E, Veerkamp JH, Glatz JF. Histochemical localization of heart-type fatty acid-binding protein in human and murine tissues. Histochem Cell Biol 1995;103:147-56.
(24.) Maatman RG, van de Westerlo EM, van Kuppevelt TH, Veerkamp JH. Molecular identification of the liver- and the heart-type fatty acid-binding proteins in human and rat kidney. Use of the reverse transcriptase polymerase chain reaction. Biochem J 1992;288: 285-90.
(25.) Pelsers MM, Hanhoff T, Van der Voort D, Arts B, Peters M, Ponds R, et al. Brain- and heart-type fatty acid-binding proteins in the brain: tissue distribution and clinical utility. Clin Chem 2004;50:1568-75.
(26.) Schreiber A, Specht B, Pelsers MM, Glatz JF, B~rchers T, Spener F. Recombinant human heart-type fatty acid-binding protein as standard in immunochemical assays. Clin Chem Med Lab 1998; 36:283-8.
(27.) Wolfrum C, Borrmann CM, Borchers T, Spener F. Fatty acids and hypolipidemic drugs regulate peroxisome proliferator-activated receptors a- and y-mediated gene expression via liver fatty acid binding protein: a signaling path to the nucleus. Proc Natl Acad Sci U S A 2001;98:2323-8.
(28.) Glatz JF, Storch J. Unraveling the significance of cellular fatty acid-binding proteins. Curr Opin Lipidol 2001;12:267-74.
(29.) van Breda E, Keizer HA, Vork MM, Surtel DA, de Jong YF, van der Vusse GJ, et al. Modulation of fatty-acid-binding protein content of rat heart and skeletal muscle by endurance training and testosterone treatment. Pflugers Arch 1992;421:274-9.
(30.) Glatz JF, van Breda E, Keizer HA, de Jong YF, Lakey JR, Rajotte RV, et al. Rat heart fatty acid-binding protein content is increased in experimental diabetes. Biochem Biophys Res Commun 1994; 199:639-46.
(31.) Wodzig KW, Pelsers MM, van der Vusse GJ, Roos W, Glatz JF. One-step enzyme linked immunosorbent assay (ELISA) for plasma fatty acid-binding protein. Ann Clin Biochem 1997;34:263-8.
(32.) de Groot MJ, Wodzig KW, Simoons ML, Glatz JF, Hermens WT. Measurement of myocardial infarct size from plasma fatty acid-binding protein or myoglobin, using individually estimated clearance rates. Cardiovasc Res 1999;44:315-24.
(33.) Ohkaru Y, Asayama K, Ishii H, Nishimura S, Sunahara N, Tanaka T, et al. Development of a sandwich enzyme-linked immunosorbent assay for the determination of human heart type fatty acid-binding protein in plasma and urine by using two different monoclonal antibodies specific for human heart fatty acid-binding protein. J Immunol Methods 1995;178:99-111.
(34.) Sanders GT, Schouten Y, de Winter RJ. Evaluation of human heart type fatty acid-binding protein assay for the early detection of myocardial infarction [Abstract]. Clin Chem 1998;44(Suppl 6):A132.
(35.) Fiebig M, Dodge M, Mangion J. Characterization and development of a COBAS EIA to quantitate human heart fatty acid-binding protein for the early detection of acute myocardial infarction [Abstract]. Clin Chem 1997;43(Suppl 6):S158.
(36.) Speijer H, Laterveer-Vreeswijk RH, Glatz JF, Nieuwenhuizen W, Hermens WT. One-step immunoassay for measuring protein concentrations in plasma, based on precipitate-enhanced ellipsometry. Anal Biochem 2004;326:257-61.
(37.) Chan CP, Sum KW, Cheung KY, Glatz JF, Sanderson JE, Hempel A, et al. Development of a quantitative lateral-flow assay for rapid detection of fatty acid-binding protein. J Immunol Methods 2003; 279:91-100.
(38.) Chan CPY, Cheng WS, Glatz JFC. Early diagnosis of acute myocardial infarction using immunosensors and immunotests. Anal Lett 2003;36:1987-2004.
(39.) Watanabe T, Ohkubo Y, Matsuoka H, Kimura H, Sakai Y, Ohkaru Y, et al. Development of a simple whole blood panel test for detection of human heart-type fatty acid-binding protein. Clin Biochem 2001;34:257-63.
(40.) Siegmann-Thos C, Renneberg R, Glatz JFC, Spener F. Enzyme immunosensors for diagnosis of myocardial infarction. Sensors Actuators 1996;B30:71-6.
(41.) Kunz U, Kasterlamp A, Renneberg R, Spener F, Cammann K. Sensing fatty acid-binding protein with planar and fiber-optical surface plasmon resonance spectroscopy devices. Sensors Actuators 1996;32:129-55.
(42.) Schreiber A, Feldbriigge R, Key G, Glatz JF, Spener F. An immunosensor based on disposable electrodes for rapid estimation of fatty acid-binding protein, an early marker of myocardial infarction. Biosens Bioelectron 1997;12:1131-7.
(43.) Key G, Schreiber A, Feldbrugge R, McNeil CJ, Jorgensen P, Pelsers MM, et al. Multicenter evaluation of an amperometric immunosensor for plasma fatty acid-binding protein: an early marker for acute myocardial infarction. Clin Biochem 1999;32:229-31.
(44.) O'Regan TM, Pravda M, O'Sullivan CK, Guilbault GG. Development of a disposable immunosensor for the detection of human heart-type fatty acid-binding protein in whole blood using screen-printed carbon electrodes. Talanta 2002;57:501-10.
(45.) Van der Voort D, Pelsers MM, Kort J, Hermens WT, Glatz JFC. Development of a displacement immunoassay for human heart-type fatty acid-binding protein in plasma: the basic conditions. Biosens Bioelectron 2003;19:465-71.
(46.) Glatz JF, Kleine AH, van Nieuwenhoven FA, Hermens WT, van Dieijen-Visser MP, van der Vusse GJ. Fatty-acid-binding protein as a plasma marker for the estimation of myocardial infarct size in humans. Br Heart J 1994;71:135-40.
(47.) Pelsers MM, Chapelle JP, Knapen M, Vermeer C, Muijtjens AM, Hermens WT, et al. Influence of age and sex and day-to-day and within-day biological variation on plasma concentrations of fatty acid-binding protein and myoglobin in healthy subjects. Clin Chem 1999;45:441-3.
(48.) Chen IW, David R, Maxon HR, Sperling M, Stein EA. Age-, sex- and race-related differences in myoglobin concentrations in the serum of healthy persons. Clin Chem 1980;26:1864-8.
(49.) Pagani F, Bonora R, Bonetti G, Panteghini M. Evaluation of a sandwich enzyme-linked immunosorbent assay for the measurement of serum heart fatty acid-binding protein. Ann Clin Biochem 2002;39:404-5.
(50.) Glatz JF, van Bilsen M, Paulussen RJ, Veerkamp J, van der Vusse GJ, Reneman RS. Release of fatty acid-binding protein from isolated rat heart subjected to ischemia and repertusion or to the calcium paradox. Biochim Biophys Acta 1988;961:148-52.
(51.) Alpert JS, Thygesen K, Antman E, Bassand JP. Myocardial infarction redefined--a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. J Am Coll Cardiol 2000;36:959-69.
(52.) Hermens WT. Mechanisms of protein release from injured heart muscle. Dev Cardiovasc Med 1998;205:85-98.
(53.) Pelsers MM, Hermens WT, Glatz JF. Fatty acid-binding proteins as plasma markers of tissue injury. Clin Chim Acta 2005;352:15-35.
(54.) Okamoto F, Sohmiya K, Ohkaru Y, Kawamura K, Asayama K, Kimura H, et al. Human heart-type cytoplasmic fatty acid-binding protein (H-FABP) for the diagnosis of acute myocardial infarction. Clinical evaluation of H-FABP in comparison with myoglobin and creatine kinase isoenzyme MB. Clin Chem Lab Med 2000;38:231-8.
(55.) Chan CP, Sanderson JE, Glatz JF, Cheng WS, Hempel A, Renneberg R. A superior early myocardial infarction marker-human heart-type fatty acid-binding protein. Z Kardiol 2004;93:388-97.
(56.) Seino Y, Tomita Y, Takano T, Ohbayashi K; Tokyo Rapid-Test Office Cardiologists (Tokyo-ROC) Study. Office cardiologists cooperative study on whole blood rapid panel tests in patients with suspicious acute myocardial infarction: comparison between heart-type fatty acid-binding protein and troponin T tests. Circ J 2004;68:144-8.
(57.) Haastrup B, Gill S, Kristensen SR, Jorgensen PJ, Glatz JF, Haghfelt T, et al. Biochemical markers of ischemia for the early identification of acute myocardial infarction without ST segment elevation. Cardiology 2000;94:254-61.
(58.) Van Nieuwenhoven FA, Kleine AH, Wodzig WH, Hermens WT, Kragten HA, Maessen JG, et al. Discrimination between myocardial and skeletal muscle injury by assessment of the plasma ratio of myoglobin over fatty acid-binding protein. Circulation 1995;92:2848-54.
(59.) Sorichter S, Mair J, Koller A, Pelsers MM, Puschendorf B, Glatz JF. Early assessment of exercise induced skeletal muscle injury using plasma fatty acid binding protein. Br J Sports Med 1998;32:121-4.
(60.) Yuan Y, Kwong AW, Kaptein WA, Fong C, Tse M, Glatz JF, et al. The responses of fatty acid-binding protein and creatine kinase to acute and chronic exercise in junior rowers. Res Q Exerc Sport 2003;74:277-83.
(61.) Kragten JA, Hermens WT, van Dieijen-Visser MP. Cardiac troponin T release into plasma after acute myocardial infarction: only fractional recovery compared with enzymes. Ann Clin Biochem 1996;33:314-23.
(62.) Wodzig KW, Kragten JA, Modrzejewski W, Gorski J, van Dieijen-Visser MP, Glatz JF, et al. Thrombolytic therapy does not change the release ratios of enzymatic and non-enzymatic myocardial marker proteins. Clin Chim Acta 1998;272:209-23.
(63.) Ishii J, Nagamura Y, Nomura M, Wang JH, Taga S, Kinoshita M, et al. Early detection of successful coronary repertusion based on serum concentration of human heart-type cytoplasmic fatty acid-binding protein. Clin Chim Acta 1997;262:13-27.
(64.) de Lemos JA, Antman EM, Morrow DA, Llevadot J, Giugliano RP, Coulter SA, et al. Heart-type fatty acid binding protein as a marker of reperfusion after thrombolytic therapy. Clin Chim Acta 2000; 298:85-97.
(65.) De Groot MJ, Muijtjens AM, Simoons ML, Hermens WT, Glatz JFC. Assessment of coronary repertusion in patients with myocardial infarction using fatty acid-binding proteins concentrations in plasma. Heart 2001;85:278-85.
(66.) Hayashida N, Chihara S, Akasu K, Oda T, Tayama E, Kai E, et al. Plasma and urinary levels of heart fatty acid-binding protein in patients undergoing cardiac surgery. Jpn Circ J 2000;64:18-22.
(67.) Setsuta K, Seino Y, Ogawa T, Arao M, Miyatake Y, Takano T. Use of cytosolic and myofibril markers in the detection of ongoing myocardial damage in patients with chronic heart failure. Am J Med 2002;113:717-22.
(68.) Pelsers MMAL. Fatty acid-binding protein as plasma marker for tissue injury [PhD thesis]. Maastricht, The Netherlands: Maastricht University, 2004.
(69.) Goto T, Takase H, Toriyama T, Sugiura T, Sato K, Ueda R, et al. Circulating concentrations of cardiac proteins indicate the severity of congestive heart failure. Heart 2003;89:1303-7.
(70.) Ishii J, Nakamura Y, Naruse H. Heart-type fatty acid-binding protein is a useful marker for diagnosis of acute myocardial infarction and risk stratification of cardiac mortality and cardiac events in patients with early hours of acute coronary syndrome. Circulation 2003;18:IV-316.
(71.) Erlikh A, Trifonov I, Katrukha A, Gratsianskii N. Prognostic value of serum heart fatty acid-binding protein in patients with non-ST elevation acute coronary syndrome: results of follow-up for 6 months. Circulation 2003;18:IV-648.
(72.) Tambara K, Fujita M, Miyamoto S, Doi K, Nishimura K, Komeda M. Pericardial fluid level of heart-type cytoplasmic fatty acid-binding protein (H-FABP) is an indicator of severe myocardial ischemia. Int J Cardiol 2004;93:281-4.
(73.) Katrukha A, Bereznikova A, Filatov V. Development of sandwich time-resolved immuno-fluorometric assay for the quantitative determination of fatty acid-binding protein (FABP) [Abstract]. Clin Chem 1997;43(Suppl 6):S106.
(74.) Robers M, Van der Hulst FF, Fischer MA, Roos W, Salud CE, Eisenwiener HG, et al. Development of a rapid microparticle-enhanced turbidimetric immunoassay for plasma fatty acid-binding protein, an early marker of acute myocardial infarction. Clin Chem 1998;44:1564-7.
(75.) Koelemay MJ, Gorgels JP, van Vlies B, Smits R, Tijssen JG, Haagen FD. Failure of new biochemical markers to exclude acute myocardial infarction at admission. Lancet 1993;342: 1220-2.
(76.) Kleine AH, Glatz JF, Van Nieuwenhoven FA, Van der Vusse GJ. Release of heart fatty acid-binding protein into plasma after acute myocardial infarction in man. Mol Cell Biochem 1992;116:155-62.
(77.) Wodzig KW, Kragten JA, Hermens WT, Glatz JF, van Dieijen-Visser MP. Estimation of myocardial infarct size from plasma myoglobin or fatty acid-binding protein. Influence of renal function. Eur J Clin Chem Clin Biochem 1997;35:191-8.
HASSAN M.E. AZZAZY,  * MAURICE M.A.L. PELSERS,  and ROBERT H. CHRISTENSON 
Table 1. Serum and intracellular concentrations of H-FABP and [FFA.sub.u] under physiologic and pathophysiologic conditions. Physiologic conditions Plasma concentrations FABP 0-6 [micr]g/L [FFA.sub.u] 7.5 (2.5) nmol/L (13) Intracellular concentrations FABP 500 [micro]g/g (22) [FFA.sub.u] Normal Main source of myocytic ATP Anaerobic metabolism ([beta]-oxidation of fatty acids) Ischemia Necrosis Plasma concentrations FABP 6-20 [micro]g/L (72) 6-2000 [micro]g/L (47) FFAu High High Intracellular concentrations FABP Low Very low [FFA.sub.u] High Low Main source of myocytic ATP Aerobic metabolism (accumulation of lactate) Table 2. Clinical use of FFAu measurements. Clinical use Study description Findings Marker of ischemia [FFA.sub.u] measured [FFA.sub.u] in 22 patients before increased 14-fold over and 30 min after baseline concentrations; coronary angioplasty highest concentrations were observed in patients with ischemic ST-segment changes Marker of ischemia 458 patients enrolled Sensitivity of in TIMI II trial; [FFA.sub.u] was 91% at blood was collected admission and 98% at 50 at presentation and min after tPA (cutoff, 5 50 min, 5 h, and 8 h nmol/L); specificity was after tPA 93% for noncardiovascular patients and healthy persons; higher [FFA.sub.u] concentrations correlated with mortality (4-fold higher rate of death) Prognostic value 5250 men, followed for [FFA.sub.u] were found to 22 years; [FFA.sub.u] be an independent risk concentrations were factor for sudden death measured (OR (a) = 1.70; 95% CI, 1.21-2.13) Clinical use Conclusions/Comments Reference Marker of ischemia Abnormal [FFA.sub.u] -15 concentrations may be a sensitive marker of cardiac ischemia Marker of ischemia Increased [FFA.sub.u] -20 may be a sensitive marker of cardiac ischemia Prognostic value [FFA.sub.u] may have -17 an arrhythmogenic role and contribute to a higher frequency of premature ventricular complexes and may therefore contribute to death (a) OR, odds ratio; CI, confidence interval. Table 3. Characteristics of immunoassays for human H-FABP. Assay Assay time, min Sample Calibration range, [micro]g/L ELISA 45 Serum; plasma 0-60 IFMA (a) 50 Serum; plasma 0-300 EIA Serum; plasma 0-100 Immunosensor 20 Plasma 0-350 Latex 10 Serum; plasma 0-150 Lateral flow 15 Whole blood Immunosensor 50 Whole blood 0-250 Lateral flow 15 Whole blood 0-125 Assay Detection limit, URL, Year [micro]g/L [micro]g/L (Reference) ELISA 0.3 6 1997 (31) IFMA (a) 0.1 6 1997 (73) EIA 1 7 1997 (35) Immunosensor 5 10 1997 (42) Latex 1.1 14 1998 (74) Lateral flow 6.2 6.2 2001 (39) Immunosensor 4 2002 (44) Lateral flow 2.8 7 2003 (37) (a) IFMA, immunofluorometric assay; EIA, enzyme immunoassay. Table 4. Key clinical uses of H-FABP. Clinical use Study description Findings Early marker of MI H-FABP was measured In 18 of 22 AMI patients, in samples from 22 AMI patients H-FABP concentrations were at or above threshold in samples taken 3.5 h after first onset of symptoms Urinary marker Serum and urinary H-FABP was significantly of AMI concentrations of increased in serum H-FABP were and urine samples determined in serial obtained 5-10 h after samples obtained from symptoms developed 11 AMI patients and decreased sharply afterward Marker of H-FABP, CK-MB, and The time to peak after myocardial injury TnT concentrations aortic declamping was after cardiac were measured shorter for H-FABP surgery in blood samples [1.4 (0.5) h than for serially collected CK-MB 2.5 (0.5) h from 10 patients and TnT 6.6 (1.3) h undergoing CABGa Detection of H-FABP and myoglobin The predictive accuracies coronary concentrations were for H-FABP ratios > 1.8 reperfusion measured in serum for detection of samples from 45 reperfusion within 15, patients with AMI 30, and 60 min of treated with initiation of treatment intracoronary were 93%, 98%, and thrombolysis or 100%, respectively direct PCTA Infarct sizing H-FABP and myoglobin In 15 AMI patients with concentrations, normal renal function, CK-MB activity, and agreement was good HBDH were assayed between infarct size serially in plasma estimated from H-FABP samples obtained or myoglobin curves from 20 AMI patients and that estimated with CK-MB or HBDH Clinical use Conclusions/Comments Reference Early marker of MI Within 0.5-3.5 h after symptom -76 onset, H-FABP had > 80% sensitivity for AMI diagnosis In a different study, sensitivity of CK-MB, CK mass, or CK activity and troponins within 0-6 h of symptom onset was reported to be < 65% (75) Urinary marker H-FABP is a urinary marker of -2 of AMI myocardial injury; H-FABP is eliminated from the circulation by the kidneys, but the exact mechanism is unknown; the only other urinary cardiac marker tested was myoglobin Marker of H-FABP may be an early marker -66 myocardial injury of myocardial injury in after cardiac patients undergoing cardiac surgery surgery Detection of H-FABP and myoglobin ratios -63 coronary had similar predictive reperfusion accuracies for early detection of successful coronary reperfusion Infarct sizing Serial plasma H-FABP or -77 myoglobin concentrations may be used for infarct sizing within the first 24 h after symptom onset only in AMI patients with normal renal function (a) CABG, coronary artery bypass grafting; HBDH, hydroxybutyrate dehydrogenase.
|Printer friendly Cite/link Email Feedback|
|Author:||Azzazy, Hassan M.E.; Pelsers, Murice M.A.L.; Christenson, Robert H.|
|Article Type:||Clinical report|
|Date:||Jan 1, 2006|
|Previous Article:||Recommendations for improving serum creatinine measurement: a report from the Laboratory Working Group of the National Kidney Disease Education...|
|Next Article:||Measurement of procarboxypeptidase U (TAFI) in human plasma: a laboratory challenge.|